Nature Communications (Nov 2017)
Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
- Marco Segatto,
- Raffaella Fittipaldi,
- Fabrizio Pin,
- Roberta Sartori,
- Kyung Dae Ko,
- Hossein Zare,
- Claudio Fenizia,
- Gianpietro Zanchettin,
- Elisa Sefora Pierobon,
- Shinji Hatakeyama,
- Cosimo Sperti,
- Stefano Merigliano,
- Marco Sandri,
- Panagis Filippakopoulos,
- Paola Costelli,
- Vittorio Sartorelli,
- Giuseppina Caretti
Affiliations
- Marco Segatto
- Department of Biosciences, Universita’ degli Studi di Milano
- Raffaella Fittipaldi
- Department of Biosciences, Universita’ degli Studi di Milano
- Fabrizio Pin
- Department of Clinical and Biological Sciences, Unit of General and Clinical Pathology, University of Turin
- Roberta Sartori
- Department of Biomedical Sciences, University of Padova
- Kyung Dae Ko
- Laboratory of Muscle Stem Cells and Gene Regulation, NIH/NIAMS
- Hossein Zare
- Laboratory of Muscle Stem Cells and Gene Regulation, NIH/NIAMS
- Claudio Fenizia
- Department of Biosciences, Universita’ degli Studi di Milano
- Gianpietro Zanchettin
- Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua
- Elisa Sefora Pierobon
- Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua
- Shinji Hatakeyama
- Musculoskeletal Disease Area, Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG
- Cosimo Sperti
- Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua
- Stefano Merigliano
- Department of Surgery, Oncology and Gastroenterology, 3rd Surgical Clinic, University of Padua
- Marco Sandri
- Venetian Institute of Molecular Medicine
- Panagis Filippakopoulos
- Structural Genomics Consortium, Old Road Campus Research Building, Nuffield Department of Medicine, University of Oxford
- Paola Costelli
- Department of Clinical and Biological Sciences, Unit of General and Clinical Pathology, University of Turin
- Vittorio Sartorelli
- Laboratory of Muscle Stem Cells and Gene Regulation, NIH/NIAMS
- Giuseppina Caretti
- Department of Biosciences, Universita’ degli Studi di Milano
- DOI
- https://doi.org/10.1038/s41467-017-01645-7
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 16
Abstract
Cachexia is a metabolic syndrome leading to muscle and adipose tissue loss in majority of cancer patients. Here the authors show that, in a mouse model, BET inhibitor JQ1 counteracts muscle and adipose tissue wasting tempering cachexia and prolonging survival through a mechanism unrelated to tumour growth.
